HUP0300379A2 - Készítmény osteoarthritis kezelésére - Google Patents

Készítmény osteoarthritis kezelésére

Info

Publication number
HUP0300379A2
HUP0300379A2 HU0300379A HUP0300379A HUP0300379A2 HU P0300379 A2 HUP0300379 A2 HU P0300379A2 HU 0300379 A HU0300379 A HU 0300379A HU P0300379 A HUP0300379 A HU P0300379A HU P0300379 A2 HUP0300379 A2 HU P0300379A2
Authority
HU
Hungary
Prior art keywords
usually
day
composition
several times
case
Prior art date
Application number
HU0300379A
Other languages
English (en)
Inventor
Yoshizou Maeda
Koji Ogawa
Yasuo Yonetomi
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of HUP0300379A2 publication Critical patent/HUP0300379A2/hu
Publication of HUP0300379A3 publication Critical patent/HUP0300379A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya osteoarthritis kezelésére és/vagy megelőzéséreszolgáló, hatóanyagként N-hidroxi-5-(etoxi-metoxi)-2(S)-metil-4(S)-[(4-fenoxi-benzoil)-amino]-valeramidot vagy egy nem toxikus sójáttartalmazó készítmény. A készítményt általában szisztémásan vagyhelyileg, rendszerint orálisan vagy parenterálisan alkalmazzák. Orálisalkalmazás esetében humán felnőttnél a napi adag általában 1 mg és1000 mg között van, naponta néhányszori alkalommal adva; parenterálisalkalmazás esetében 0,1 mg és 100 mg között, napi néhányszorialkalommal adva, vagy intravénásan 1-24 órán át folyamatosan adva. Ó
HU0300379A 2000-02-10 2001-02-09 Composition for degenerative arthritis HUP0300379A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000033422 2000-02-10
PCT/JP2001/000914 WO2001058440A1 (fr) 2000-02-10 2001-02-09 Medicaments pour le traitement de l'arthrite degenerative

Publications (2)

Publication Number Publication Date
HUP0300379A2 true HUP0300379A2 (hu) 2003-07-28
HUP0300379A3 HUP0300379A3 (en) 2004-08-30

Family

ID=18557910

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300379A HUP0300379A3 (en) 2000-02-10 2001-02-09 Composition for degenerative arthritis

Country Status (14)

Country Link
US (1) US20030114530A1 (hu)
EP (1) EP1293202A4 (hu)
KR (1) KR20020074513A (hu)
CN (1) CN1400895A (hu)
AU (1) AU2001232258A1 (hu)
BR (1) BR0108133A (hu)
CA (1) CA2400243A1 (hu)
HU (1) HUP0300379A3 (hu)
MX (1) MXPA02007736A (hu)
NO (1) NO20023793L (hu)
NZ (1) NZ520711A (hu)
RU (1) RU2002121504A (hu)
WO (1) WO2001058440A1 (hu)
ZA (1) ZA200206320B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003013494A1 (ja) * 2001-08-06 2004-11-25 小野薬品工業株式会社 変形性関節症治療剤
JP2006503811A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ
KR100970676B1 (ko) * 2009-11-30 2010-07-15 (주) 골프존 스크린 골프용 스크린
KR100972822B1 (ko) * 2009-11-30 2010-07-28 (주) 골프존 스크린 골프용 투과형 스크린 및 이를 구비하는 스크린 골프 시스템

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用
CN1304402A (zh) * 1998-04-03 2001-07-18 三共株式会社 磺酰胺衍生物

Also Published As

Publication number Publication date
RU2002121504A (ru) 2004-03-20
AU2001232258A1 (en) 2001-08-20
EP1293202A1 (en) 2003-03-19
NO20023793D0 (no) 2002-08-09
US20030114530A1 (en) 2003-06-19
CA2400243A1 (en) 2001-08-16
NZ520711A (en) 2004-03-26
HUP0300379A3 (en) 2004-08-30
EP1293202A4 (en) 2004-12-22
CN1400895A (zh) 2003-03-05
WO2001058440A1 (fr) 2001-08-16
ZA200206320B (en) 2003-11-07
KR20020074513A (ko) 2002-09-30
BR0108133A (pt) 2003-02-25
NO20023793L (no) 2002-10-09
MXPA02007736A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
HUP0203520A2 (hu) Bisz-acil-amidokat tartalmazó szilárd kozmetikai vagy gyógyszerészeti készítmény
HUP0102160A2 (hu) Alfa-keto-enamin-származékok alkalmazása alkotórészként
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
PL356358A1 (en) Solid dosage form of someticone for oral administration
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
BG103947A (en) Derivatives of 9-oxymerythromycin
WO2002094774A3 (en) Oxcarbazepine dosage forms
SG162605A1 (en) Pharmaceutical compositions
HUP0105364A2 (hu) Spontán diszpergálódó N-benzoil sztaurosporint tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CA2484494A1 (en) High dose ibandronate formulation
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
HUP0300379A2 (hu) Készítmény osteoarthritis kezelésére
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
HUP0202119A2 (hu) OCIF-ot és poliszacharidot tartalmazó komplex
DE60221989D1 (de) Mundpflegemittel enthaltend einen fluor-ion-vektor und ein antioxidationsmittel
WO2001066102A3 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees